A screaming buy or a stock to steer clear of?
Image source: Getty Images
CSL Ltd (ASX: CSL) shares closed at $209.25 on Friday, down 23% since the biotechnology giant released its FY25 report last month.
Investors were rattled by the company’s wide-ranging plans to restructure the business, including the demerger of Seqirus.
Many issues, particularly in terms of research and development (R&D), have caused problems for CSL in recent years.
The failure of the CSL112 heart drug candidate in trials, declining vaccine rates post-COVID, weakness in the Behring blood plasma business, and disappointing results from Vifor, the nephrology business acquired for US$11.7 billion in 2021, have taken their toll.
‘We need to fix this’: CSL chair
In the Australian Financial Review (AFR) last…
